Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Klin Lab Diagn ; (6): 36-9, 2011 Jun.
Article in Russian | MEDLINE | ID: mdl-21851009

ABSTRACT

The ability of the synthetic peptide IMG-5, that reproduces one of the antigenic determinants of the protein filaggrin, to show antigenic activity was studied when anti-cyclic citrullinated peptide antibodies (ACCPAb) to filaggrin were found in the serum samples of patients with rheumatoid arthritis (RA). The binding of IMG-5 to ACCPAb has been shown to be specific (dose-dependent and reversible). The serum samples from patients with RA, controls, and donors show a significant difference in the interaction of the synthetic peptide with ACCPAb (p < 0.005 and p < 0.0001, respectively). The level of IgM rheumatoid factor (RF) detected in patients with RA differs greatly from that in the controls. In the patients with RA versus the controls, the specificity of ACCPAb determination was as high as 87; and the sensitivity was 40.5%. When ACCPAbs were determined using the commercial kit CCP, the specificity and sensitivity were 94 and 47.3%, respectively. The specificity of RF detection was equal to 50% and the sensitivity was 70%. The sensitivity of the test using IMG-5 is a maximum in X-ray stage IRA (69.2%) and falls in its stage III (26.7%). On the contrary, the sensitivity of the commercial kit and RF determination increases from X-ray stage I (46.2 and 53.8%, respectively) to II (66.7 and 80%). The sensitivity of the used tests in varying RA activities has demonstrated that they are most effective in patients with moderate RA activity. The concurrent detection of ACCPAb and RF increases the probability of differentiating RA from other rheumatic diseases.


Subject(s)
Arthritis, Rheumatoid/blood , Autoantibodies/blood , Intermediate Filament Proteins/immunology , Peptides, Cyclic/immunology , Adult , Aged , Arthritis, Rheumatoid/diagnosis , Enzyme-Linked Immunosorbent Assay , Female , Filaggrin Proteins , Humans , Immunoglobulin M/blood , Immunoglobulin M/immunology , Male , Middle Aged , Rheumatoid Factor/blood , Sensitivity and Specificity
2.
Bull Exp Biol Med ; 151(5): 615-8, 2011 Sep.
Article in English | MEDLINE | ID: mdl-22462059

ABSTRACT

Immunogenic characteristics of filaggrin protein molecule as an antigen for antibodies to filaggrin, markers of early rheumatoid arthritis, were studied. Two new peptide motives, possible epitopes for antibodies to filaggrin, were shown in the filaggrin molecule by predictive analysis using programmed algorithms. Only IMG-3 and its cyclic form IMG-4 exhibited antigenic reactivity with sera from rheumatoid arthritis patients, differing significantly from the reactivity with donor sera. The immunogenic characteristics of IMG-3 differed from the characteristics of a previously described epitope.


Subject(s)
Arthritis, Rheumatoid/immunology , Epitopes/immunology , Intermediate Filament Proteins/immunology , Peptide Fragments/immunology , Amino Acid Motifs/immunology , Amino Acid Sequence , Arthritis, Rheumatoid/blood , Case-Control Studies , Epitope Mapping , Epitopes/chemistry , Fibrin/chemistry , Filaggrin Proteins , Humans , Intermediate Filament Proteins/chemistry , Molecular Sequence Data , Peptide Fragments/chemistry , Protein Binding , Sequence Analysis, Protein , Sequence Homology, Amino Acid
3.
Bull Exp Biol Med ; 148(3): 470-3, 2009 Sep.
Article in English, Russian | MEDLINE | ID: mdl-20396715

ABSTRACT

Antiinflammatory and analgesic effects of artrofoon in osteoarthritis and the absence of side effects were demonstrated. The maximum antiinflammatory effect was attained by the end of the 3rd month of artrofoon treatment. The effect persisted from 6 months to 2 years against the background of maintaining therapy with artroofoon.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Antibodies, Monoclonal/therapeutic use , Osteoarthritis/drug therapy , Tumor Necrosis Factor-alpha/immunology , Aged , Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/immunology , Dose-Response Relationship, Drug , Dose-Response Relationship, Immunologic , Female , Humans , Middle Aged , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...